• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Case Studies

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

How Syngene's safety tox package helped Cytopeutics to advance its cell therapy drug to the Clinic

Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.

 

How Syngene developed a multi-drug combination, antiparasitic drug for dogs for a leading Animal Health company

Learn how Syngene developed an antiparasitic tablet for dogs containing multiple APIs (one of which is a very low dose) in just six months.

How Syngene helped develop the world’s first drug for a rare disease affecting children

Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.

How Syngene helped Panbela achieve shorter production time for its pancreatic cancer drug

Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing

A quick, cost-effective process for large-scale compound synthesis for a leading pharma company

How Syngene achieved cost minimization and quick turn-around time when scaling a client’s drug compound from lab-scale to cGMP-scale using the ‘SELECT’ criteria.

How Syngene helped a global biopharma fast-track novel molecule development

Learn how a partnership with a leading global biopharma for outsourced Bioanalytical studies for Large Molecule therapeutics evolved into a co-development partnership nearing a decade.

The many benefits of outsourcing Stability: A Baxter-Syngene Case study

Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented, which enabled a mutully successful collaboration.

Multidrug combo for companion animals

Learn how Syngene developed and commercialized for its client, a complex palatable dosage form comprising three actives for use in companion animals.

Harnessing Targeted Protein Degradation

Read how Syngene’s partnership with a leading Biotech company working in the field  of cancer therapy, grew from one small pilot project to over  100 FTEs today. 

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details